Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

Completed · Phase 3

Conditions studied: Ureteral Stent Discomfort

In brief

To assess the impact of alfuzosin vs. placebo on ureteral stent discomfort, urinary symptoms and quality of life.

Key facts

Study ID

NCT00467467

Run by

University of Minnesota

People needed

60

Starts

2006-06-01

Expected to finish

2007-10-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18
• Undergoing unilateral retrograde ureteroscopy with ureteral stent placement

You may not qualify if…

• Significant ureteral trauma
• Concomitant ESWL or other secondary surgical procedure than may impact patient comfort
• Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets.
• Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study
• Undergoing bilateral ureteral stenting
• Undergoing antegrade ureteral stenting
• Undergoing simultaneous extracorporeal shockwave lithotripsy
• Urinary infection (fever >101, positive urine culture, many bacteria on urinalysis)
• Primary bladder dysfunction that would impact ability to void without a catheter
• Neurologic dysfunction that would impair pain sensation
• History of chronic pain or substance abuse
• Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased
• Other alpha-blockers
• Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.